PRRT2相关:从自我限制的婴儿到非典型的现象
Madeline Komar1, Jashanpreet Sidhu2,3,4, Jiju Joseph5
1Division of Neurology, Department of Paediatrics, McMaster University, Hamilton, Ontario, Canada.
Neurology. Genetics
|May 22, 2025
概括
在PRRT2基因的致病变体通常会导致自我限制的婴儿 (SeLIE). 然而,非典型现型和16p11.2微删除也可能发生,突出显示需要进一步的基因型-现型相关性.
科学领域:
- 遗传学 是一个遗传学.
- 神经学 神经学
- 是一种病.
背景情况:
- PRRT2基因的致病变体是已知的自限婴儿 (SeLIE) 的原因之一.
- 最近的发现表明,与PRRT2基因变异相关的现象的范围更广.
- 国际合作对于理解这些多样化的演示是至关重要的.
研究的目的:
- 探索PRRT2相关的全部表型谱.
- 调查PRRT2变体,16p11.2微删除和现象之间的关联.
- 为了确定PRRT2相关的基因型-表型相关性.
主要方法:
- 追溯性研究包括患有的儿童和一种致病性PRRT2变体或包括PRRT2在内的16p11.2微删除.
- 对的特征,并发症,遗传发现,EEG/神经成像和治疗反应进行全面的数据收集.
- 分析了40个儿科病例,并详细总结了研究结果.
主要成果:
- 确定了40名儿童,其中90%患有病原性PRRT2变体,10%患有16p11.2微删除.
- SeLIE是最常见的诊断,在97%的异性PRRT2变体病例中观察到,100%的同性变体病例,以及75%的微删除病例.
- 在3名患有异性PRRT2变异的儿童中,观察到非典型的表型,包括婴儿和焦点. 同胞性PRRT2变体与运动障碍的SeLIE有关.
结论:
- 致病性PRRT2变异与SeLIE有很强的关联,但不同的现型可以表现出来.
- 染色体微阵列可能有利于检测因表型重叠而导致异构PRRT2变异的患者的16p11.2微切除.
- 需要对更多病例进行进一步的研究,以充分阐明与16p11.2微切除和各种PRRT2变体类型 (同性/复合异性) 相关的谱.
相关概念视频
Seizures l: Introduction
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Epilepsy ll: Types
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Seizures ll: Types
Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
Seizures: Classification
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...


